- Category Material JettingProcess Development
- Pixdro LP50
- ImageXpert Dropwatcher
Additive Manufacturing offers the pharmaceutical industry significant opportunities to create novel products with unique benefits for patients. However, there is a major challenge in demonstrating the viability and scalability of using ink jet printheads. This project aims to overcome these challenges and build confidence in the potential opportunities for ink jet technology in the pharmaceutical industry.
Of the various AM technologies that have been investigated in academic environments, inkjet processes offer the most opportunity of scaling to mass production. However, the research that has been undertaken in this area to date remains at TRL2-4; there is a major challenge in demonstrating the viability and scalability of using ink jet printheads for the mass production of pharmaceutical products. Until this feasibility is demonstrated, pharmaceutical companies will not have sufficient confidence to invest further in this technology and commercialisation is unlikely to occur.
This project will show that inkjet technologies are capable of operating under Good Manufacturing Practice (GMP) conditions, as specified by a major pharmaceutical company. A medicine-loaded ink will be printed under manufacturing conditions to assess the failure modes; through this, the project will determine if AM technology could be technically and commercially viable in the pharmaceutical manufacturing industry. The project will publicly publish data to support these findings, with the aim of building confidence and awareness within the pharmaceutical industry.
This project has been shortlisted for the collaborate to innovate awards, category Healthcare, by the Engineer. Currently in its fourth year, Collaborate to Innovate – which is supported by ESPRC – was launched to uncover and celebrate great examples of engineering collaboration – a dynamic considered critical to solving many of the challenges and problems faced by society.
“Printed pharmaceuticals represents a huge opportunity for healthcare and it’s great that Added Scientific can play a leading role in commercialising this”.